Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315


Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?

Jang TL, Kim IY, Scardino PT, Eastham JA.

Cancer. 2019 Mar 12. doi: 10.1002/cncr.32054. [Epub ahead of print] No abstract available.


Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.

Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ.

Prostate Cancer Prostatic Dis. 2018 Nov 1. doi: 10.1038/s41391-018-0106-1. [Epub ahead of print]


Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer.

Ito Y, Udo K, Vertosick EA, Sjoberg DD, Vickers AJ, Al-Ahmadie HA, Chen YB, Gopalan A, Sirintrapun SJ, Tickoo SK, Scardino PT, Eastham JA, Reuter VE, Fine SW.

J Urol. 2019 Mar;201(3):535-540. doi: 10.1016/j.juro.2018.09.060.


Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.

Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardino PT, Lin Y, Kim IY, Lu-Yao GL.

Cancer. 2018 Oct 15;124(20):4010-4022. doi: 10.1002/cncr.31726. Epub 2018 Sep 25.


Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade.

Capogrosso P, Vertosick EA, Benfante NE, Eastham JA, Scardino PJ, Vickers AJ, Mulhall JP.

Eur Urol. 2019 Feb;75(2):221-228. doi: 10.1016/j.eururo.2018.08.039. Epub 2018 Sep 17.


Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.

Dean LW, Assel M, Sjoberg DD, Vickers AJ, Al-Ahmadie HA, Chen YB, Gopalan A, Sirintrapun SJ, Tickoo SK, Eastham JA, Scardino PT, Reuter VE, Ehdaie B, Fine SW.

J Urol. 2019 Jan;201(1):77-82. doi: 10.1016/j.juro.2018.07.062.


Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.

Murray KS, Spaliviero M, Tonorezos ES, Lacouture ME, Tap WD, Oeffinger KC, Vargas HA, Eastham JA.

Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.


Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?

Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA.

J Urol. 2018 Jun;199(6):1502-1509. doi: 10.1016/j.juro.2017.12.056. Epub 2018 Jan 4.


The evolution of chemotherapy for the treatment of prostate cancer.

Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA.

Ann Oncol. 2017 Nov 1;28(11):2658-2669. doi: 10.1093/annonc/mdx348. Review.


Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.

Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, Gandaglia G, Eastham JA, Scardino PT, Vickers A, Cozzarini C, Montorsi F, Briganti A.

Eur Urol. 2018 Jun;73(6):890-896. doi: 10.1016/j.eururo.2017.09.027. Epub 2017 Oct 16.


Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.

Audenet F, Vertosick EA, Fine SW, Sjoberg DD, Vickers AJ, Reuter VE, Eastham JA, Scardino PT, Touijer KA.

J Urol. 2018 Apr;199(4):961-968. doi: 10.1016/j.juro.2017.10.010. Epub 2017 Oct 10.


Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.

Takeda T, Tin AL, Corradi RB, Mamoor M, Benfante NE, Sjoberg DD, Scardino PT, Eastham JA, Fine SW, Touijer KA.

Eur Urol. 2018 Apr;73(4):488-490. doi: 10.1016/j.eururo.2017.08.005. Epub 2017 Aug 26.


An assessment of Prostate Cancer Research International: Active Surveillance (PRIAS) criteria for active surveillance of clinically low-risk prostate cancer patients.

da Silva V, Cagiannos I, Lavallée LT, Mallick R, Witiuk K, Cnossen S, Eastham JA, Fergusson DA, Morash C, Breau RH.

Can Urol Assoc J. 2017 Aug;11(8):238-243. doi: 10.5489/cuaj.4093.


Periprostatic adipose inflammation is associated with high-grade prostate cancer.

Gucalp A, Iyengar NM, Zhou XK, Giri DD, Falcone DJ, Wang H, Williams S, Krasne MD, Yaghnam I, Kunzel B, Morris PG, Jones LW, Pollak M, Laudone VP, Hudis CA, Scher HI, Scardino PT, Eastham JA, Dannenberg AJ.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):418-423. doi: 10.1038/pcan.2017.31. Epub 2017 Jun 27.


Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomy.

Nguyen DP, Kent M, Vilaseca A, Corradi RB, Fossati N, Sjoberg DD, Benfante N, Eastham JA, Scardino PT, Touijer KA.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):105-109. doi: 10.1038/pcan.2016.60. Epub 2016 Dec 13.


A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

O'Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC, Laudone VP, Bochner BH, Sheinfeld J, Dayan ES, Bellomo LP, Sjoberg DD, Heller G, Zelefsky MJ, Eastham JA, Scardino PT, Scher HI.

Urology. 2017 Apr;102:164-172. doi: 10.1016/j.urology.2016.10.044. Epub 2016 Nov 22.


Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA.

Cancer. 2016 Nov 15;122(21):3386-3393. doi: 10.1002/cncr.30192. Epub 2016 Jul 26.


Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.

Hashimoto T, Rahul K, Takeda T, Benfante N, Mulhall JP, Hricak H, Eastham JA, Vargas HA.

Urol Oncol. 2016 Dec;34(12):530.e9-530.e14. doi: 10.1016/j.urolonc.2016.07.004. Epub 2016 Sep 22.


Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study.

Fridriksson JÖ, Folkvaljon Y, Nilsson P, Robinson D, Franck-Lissbrant I, Ehdaie B, Eastham JA, Widmark A, Karlsson CT, Stattin P.

Scand J Urol. 2016 Oct;50(5):338-45. doi: 10.1080/21681805.2016.1194460. Epub 2016 Jun 22.


Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 Sep;95:224. doi: 10.1016/j.urology.2016.05.046. Epub 2016 Jun 1. No abstract available.


Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.

Gugliemetti G, Sukhu R, Conca Baenas MA, Meeks J, Sjoberg DD, Eastham JA, Scardino PT, Touijer K.

Actas Urol Esp. 2016 Sep;40(7):434-9. doi: 10.1016/j.acuro.2016.02.008. Epub 2016 May 13. English, Spanish.


Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study.

Lee DJ, Recabal P, Sjoberg DD, Thong A, Lee JK, Eastham JA, Scardino PT, Vargas HA, Coleman J, Ehdaie B.

J Urol. 2016 Sep;196(3):697-702. doi: 10.1016/j.juro.2016.03.149. Epub 2016 Mar 30.


Author Reply.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 May;91:17-8. doi: 10.1016/j.urology.2015.12.069. Epub 2016 Mar 15. No abstract available.


Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy.

Pietzak EJ, Eastham JA.

Curr Urol Rep. 2016 May;17(5):37. doi: 10.1007/s11934-016-0592-4. Review.


The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer.

Touijer KA, Eastham JA.

Eur Urol. 2016 Nov;70(5):738-739. doi: 10.1016/j.eururo.2016.02.047. Epub 2016 Mar 5. No abstract available.


Detection of Lymph Node Metastases with SERRS Nanoparticles.

Spaliviero M, Harmsen S, Huang R, Wall MA, Andreou C, Eastham JA, Touijer KA, Scardino PT, Kircher MF.

Mol Imaging Biol. 2016 Oct;18(5):677-85. doi: 10.1007/s11307-016-0932-2.


The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.

Recabal P, Assel M, Sjoberg DD, Lee D, Laudone VP, Touijer K, Eastham JA, Vargas HA, Coleman J, Ehdaie B.

J Urol. 2016 Aug;196(2):374-81. doi: 10.1016/j.juro.2016.02.084. Epub 2016 Feb 23.


Erectile Function Recovery after Radical Prostatectomy in Men with High Risk Features.

Recabal P, Assel M, Musser JE, Caras RJ, Sjoberg DD, Coleman JA, Mulhall JP, Parra RO, Scardino PT, Touijer K, Eastham JA, Laudone VP.

J Urol. 2016 Aug;196(2):507-13. doi: 10.1016/j.juro.2016.02.080. Epub 2016 Feb 22.


The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 May;91:12-8. doi: 10.1016/j.urology.2015.12.054. Epub 2016 Feb 2.


Prostate Cancer, Version 1.2016.

Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.


Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?

Satasivam P, Poon BY, Ehdaie B, Vickers AJ, Eastham JA.

J Urol. 2016 Jan;195(1):74-9. doi: 10.1016/j.juro.2015.07.078. Epub 2015 Jul 17.


A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA.

Eur Urol. 2016 Mar;69(3):428-35. doi: 10.1016/j.eururo.2015.06.046. Epub 2015 Jul 10.


Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance.

Anderson CB, Sternberg IA, Karen-Paz G, Kim PH, Sjoberg D, Vargas HA, Touijer K, Eastham JA, Ehdaie B.

J Urol. 2015 Dec;194(6):1607-11. doi: 10.1016/j.juro.2015.06.084. Epub 2015 Jun 26.


Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.

Anderson CB, Tin AL, Sjoberg DD, Mulhall JP, Sandhu J, Touijer K, Laudone VP, Eastham JA, Scardino PT, Ehdaie B.

BJU Int. 2016 Jun;117(6B):E46-51. doi: 10.1111/bju.13215. Epub 2015 Jul 20.


Preoperative predictive model of recovery of urinary continence after radical prostatectomy.

Matsushita K, Kent MT, Vickers AJ, von Bodman C, Bernstein M, Touijer KA, Coleman JA, Laudone VT, Scardino PT, Eastham JA, Akin O, Sandhu JS.

BJU Int. 2015 Oct;116(4):577-83. doi: 10.1111/bju.13087. Epub 2015 Mar 30.


Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.

Cha EK, Eastham JA.

Urol Oncol. 2015 May;33(5):217-25. doi: 10.1016/j.urolonc.2014.11.020. Epub 2015 Jan 14. Review.


The diffusion of minimally invasive radical prostatectomy in the United States: a case study of the introduction of new surgical devices.

Anderson CB, Elkin EB, Atoria CL, Eastham JA, Scardino PT, Touijer K.

Prostate Cancer Prostatic Dis. 2015 Mar;18(1):75-80. doi: 10.1038/pcan.2014.49. Epub 2014 Dec 16.


Standardization of patient-centered outcomes: less is more.

Ehdaie B, Eastham JA.

Eur Urol. 2015 Mar;67(3):468-9. doi: 10.1016/j.eururo.2014.10.003. Epub 2014 Oct 14. No abstract available.


Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.

Gotto GT, Yu C, Bernstein M, Eastham JA, Kattan MW.

Front Oncol. 2014 Oct 27;4:296. doi: 10.3389/fonc.2014.00296. eCollection 2014.


Significance and management of positive surgical margins at the time of radical prostatectomy.

Silberstein JL, Eastham JA.

Indian J Urol. 2014 Oct;30(4):423-8. doi: 10.4103/0970-1591.134240.


The association between nerve sparing and a positive surgical margin during radical prostatectomy.

Preston MA, Breau RH, Lantz AG, Morash C, Gerridzen RG, Doucette S, Mallick R, Eastham JA, Cagiannos I.

Urol Oncol. 2015 Jan;33(1):18.e1-18.e6. doi: 10.1016/j.urolonc.2014.09.006. Epub 2014 Oct 11.


Insignificant disease among men with intermediate-risk prostate cancer.

Hong SK, Vertosick E, Sjoberg DD, Scardino PT, Eastham JA.

World J Urol. 2014 Dec;32(6):1417-21. doi: 10.1007/s00345-014-1413-3. Epub 2014 Sep 27.


Organoid cultures derived from patients with advanced prostate cancer.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y.

Cell. 2014 Sep 25;159(1):176-187. doi: 10.1016/j.cell.2014.08.016. Epub 2014 Sep 4.


Association of anesthesia technique for radical prostatectomy with biochemical recurrence: a retrospective cohort study.

Ehdaie B, Sjoberg DD, Dalecki PH, Scardino PT, Eastham JA, Amar D.

Can J Anaesth. 2014 Dec;61(12):1068-74. doi: 10.1007/s12630-014-0221-y. Epub 2014 Aug 21.


Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.

Gondo T, Hricak H, Sala E, Zheng J, Moskowitz CS, Bernstein M, Eastham JA, Vargas HA.

Eur Radiol. 2014 Dec;24(12):3161-70. doi: 10.1007/s00330-014-3367-7. Epub 2014 Aug 7.


Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.

Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P.

Mol Cell Proteomics. 2014 Nov;13(11):3082-96. doi: 10.1074/mcp.M114.038836. Epub 2014 Jul 23.


Prostate size and adverse pathologic features in men undergoing radical prostatectomy.

Hong SK, Poon BY, Sjoberg DD, Scardino PT, Eastham JA.

Urology. 2014 Jul;84(1):153-7. doi: 10.1016/j.urology.2014.04.006.


Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, Califano A, Abate-Shen C.

Cancer Cell. 2014 May 12;25(5):638-651. doi: 10.1016/j.ccr.2014.03.017.


Prostate cancer, version 2.2014.

Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):686-718.


Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer.

Gondo T, Poon BY, Matsumoto K, Bernstein M, Sjoberg DD, Eastham JA.

BJU Int. 2015 Jan;115(1):81-6. doi: 10.1111/bju.12769. Epub 2014 Aug 13.

Supplemental Content

Loading ...
Support Center